Showing 81-90 of 381 results for "".
Easing the Burden of Proof
https://practicaldermatology.com/topics/practice-management/easing-the-burden-of-proof/23141/Dermatologists are frustrated with the burdensome prior authorization process and want change.Journal Club: A Comprehensive Update
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-a-comprehensive-update/32402/Practical Dermatology Editorial Board member Christopher Bunick, MD, FAAD, discusses the recent Lancet article "Atopic Dermatitis" with primary author Emma Guttman, MD, PhD. Guttman-Yassky E, Renert-Yuval Y, Brunner PM. Atopic dermatitis. Lancet. 2025;405(10478):583-596. doi: 10.1016/S0140-6736(24)0Helping Patients Look Like Their Best Personal Self
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/shamban/18973/Has someone come into your office asking to look radically different? That's a big red flag warning for Ava Shamban, MD, owner and director of two dermatological practices in Santa Monica and Beverly Hills, Calif., frequent TV commentator, and author of the book, “Heal Your Skin: The Breakthrough PlVitiligo Update: Pathogenesis, Therapies, and Integrative Approaches
https://practicaldermatology.com/issues/may-june-2025/vitiligo-update-pathogenesis-therapies-and-integrative-approaches/35920/Vitiligo is a chronic autoimmune condition characterized by depigmented white patches due to melanocyte destruction, attributed to genetic factors and environmental triggers.Maui Derm Panel: GLP-1 Agonists Can Help Psoriasis Patients
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/maui-derm-panel-glp-1-agonists-can-help-psoriasis-patients/32917/Only 11% of Maui Derm 2025 audience members polled said they were comfortable prescribing weight-loss drugs, and 49% said they were not at all—but they should be, according to the presenters of “Psoriasis Update 2025” at the conference in Maui, Hawaii.DermWireTV: International Launch of AviClear; Biological Effects of Air Pollution on Human Skin; New AAD Guidelines for Acne Care
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-international-launch-of-aviclear-biological-effects-of-air-pollution-on-human-skin-new-aad-guidelines-for-acne-care/20261/In this episode of DermWireTV, we report on the international launch of the first energy-based device FDA-cleared for the long-term treatment of mild, moderate, and severe acne. An expert discusses a recent study that examines the biological effects of air pollution on human skin equivalents. For thChitotriosidase: Providing Confirmation of Sarcoidosis When ACE Fails
https://practicaldermatology.com/topics/clinical-case-reports/chitotriosidase-providing-confirmation-of-sarcoidosis-when-ace-fails/26642/Chitotriosidase: Providing Confirmation of Sarcoidosis When ACE FailsDermWireTV: Pulse's CellFX, Soliton's RAP Technology, Belotero Balance (+), Restylane Defyne, Eczema Costs
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-pulses-cellfx-solitons-rap-technology-belotero-balance-restylane-defyne-eczema-costs/19899/The FDA has cleared Pulse Biosciences’ CellFX system, and a commercial rollout will begin soon. There’s another new option for treatment for legs with FDA clearance of Soliton’s Rapid Acoustic Pulse technology for cellulite. For eight percent of Americans with atopic dermatitis, annual out of pocketFDA Approvals, Acne Insights, EPI Gets Cloderm
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-fda-approvals-acne-insights-epi-gets-cloderm/18230/In a flurry of approvals, FDA gives the nod to Almirall's Seysara (sarecycline), Ortho Dermatologics' Bryhali (halobetasol propionate, 0.01%) Lotion, Paratek Pharmaceuticals' Nuzyra (omadacycline), and Regeneron's Libtayo (cemiplimab). Research shows top earners across various fields in the US mayJanssen Approvals, New Thermage FLX, Restylane Silk Cannulas
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-janssen-approvals-new-thermage-flx-restylane-silk-cannulas/18401/Janssen Biotech's Stelara is now approved for the treatment of adolescents 12 years of age or older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Janssen's SIMPONI ARIA® cleared for the treatment of adults with active psoriatic arthritis or active